The Institute for Clinical and Economic Review (ICER) has published its final evidence report for two drugs used to treat the autoimmune disease Myasthenia Gravis. The report includes cost-effectiveness, efficacy, and value assessments for eculizumab and efgartigimod.
“While our review of available evidence suggests that both eculizumab and efgartigimod appear to significantly improve function and quality of life for these patients, there are uncertainties about longer-term outcomes for efgartigimod and how it will be dosed in real-world settings. Efgartigimod’s price is not yet known, but our analysis suggests that the current list price for eculizumab is far higher than the usual thresholds for cost-effectiveness. Further, it’s important to monitor these treatments’ effectiveness in minority populations to develop a complete picture of their overall efficacy.” Read more here.
(Source: ICER, 10/21/21)